Kijimicin
CAS No. : 129297-22-9
| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-123444 |
| M.Wt: | 684.90 |
| Formula: | C37H64O11 |
| Purity: | >98 % |
| Solubility: |
Kijimicin is a polyether ionophore antibiotic originally discovered in Actinomadura sp. MI215-NF3. inhibits HIV-1 replication and reduces the infectivity of progeny viral particles. Kijimicin exhibits inhibitory activity against intracellular T. gondii (IC50 = 45.6 nM), extracellular parasites (IC50 = 216.6 pM) and C. parvum (IC50 = 7.7 nM), and controls acute T. gondii infection in mice. Kijimicin can be used for research on HIV, toxoplasmosis, cryptosporidiosis, and bacterial infections[1][2][3][4].
In Vitro:Kijimicin (7 days) inhibits HIV-1 replication in acutely infected H9 cells with an IC50 of 2.2 μg/mL, and shows little cytotoxicity (IC50 = 88 μg/mL)[1].
Kijimicin (0.1-1000 μg/mL; 72 h) inhibits HIV-1 replication in chronically infected U937 cells[1].
Kijimicin (0.01, 0.1, 1.0 μg/mL; 7 days) reduces the infectivity of progeny HIV-1 viral particles from H9 cells by more than 1 log[1].
Kijimicin exhibits antimicrobial activity against Gram-positive bacteria including Staphylococcus aureus FDA 209P (MIC < 0.78 μg/mL), Bacillus cereus ATCC 10702 (MIC < 0.78 μg/mL), and Micrococcus luteus PCI 1001 (MIC < 0.78 μg/mL)[2].
Kijimicin (7.7 nM; 48 h) inhibits C. parvum growth in HCT-8 cells with an IC50 of 7.7 nM and a CC50 > 20 μM (selectivity index = 2585)[3].
Kijimicin (1-300 nM; 72 h) inhibits intracellular T. gondii RH-GFP growth in HFF cells with an IC50 of 45.6 nM and a selectivity index of 1019.7[4].
Kijimicin (1-2000 pM; 1 h) inhibits extracellular T. gondii RH-GFP invasion into Vero cells with an IC50 of 216.6 pM and a selectivity index of 214,681.4[4].
Kijimicin (50 nM; 24 h) induces morphological changes in T. gondii tachyzoites, including cell swelling and multiple intracellular vacuole-like structures[4].
In Vivo:Kijimicin (3, 10 mg/kg; i.p.; once daily for 7 days) improves survival and alleviates clinical signs in 6-8-week-old female BALB/c mice infected with T. gondii PLK-GFP. Kijimicin sodium achieves a survival rate of 91.7% at the 10 mg/kg dose, and yields a 66.7% survival rate at the 3 mg/kg dose[4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Kijimicin
- Cat. No.:
- HY-123444
- Quantity:
Your information is safe with us.